Search research articles
Contact Us
Filters
Showing results (371-380 of 456) with videos related to
Page
of 46
Sort By:
Eclinicalmedicine
|
June 16, 2025
Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study
Fabio Tirotta, Marco Fiore, Sylvie Bonvalot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Hans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
Critical Reviews in Oncology/Hematology
|
February 21, 2018
ECCO essential requirements for quality cancer care: Melanoma
Michel W Wouters, Olivier Michielin, Esther Bastiaannet, et al.
Cancer
|
March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Lorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG
Chandrajit P Raut, Dario Callegaro, Rosalba Miceli, et al.
Annals of Surgical Oncology
|
January 3, 2021
Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG)
Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Annals of Surgical Oncology
|
April 28, 2021
Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.
Page
of 46
Search research articles
Search
Showing results (371-380 of 456) with videos related to
Sort By:
Page
of 46
Eclinicalmedicine
|
June 16, 2025
Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study
Fabio Tirotta, Marco Fiore, Sylvie Bonvalot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Hans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
Critical Reviews in Oncology/Hematology
|
February 21, 2018
ECCO essential requirements for quality cancer care: Melanoma
Michel W Wouters, Olivier Michielin, Esther Bastiaannet, et al.
Cancer
|
March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Lorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG
Chandrajit P Raut, Dario Callegaro, Rosalba Miceli, et al.
Annals of Surgical Oncology
|
January 3, 2021
Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG)
Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Annals of Surgical Oncology
|
April 28, 2021
Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.
Page
of 46